The Effect of Peripheral Blood Cell Paremeters in the Patients with Refractory/Relapsed Acute B-Lymphoblastic Leukemia Treated with CD19 -CAR- T Cells

Abstract

Abstract: Objective To study the effect of peripheral blood cell paremeters in the patients with refractory/relapsed acute B-lymphoblastic leukemia treated with CD19 chimeric antigen receptor T cells (CD19-CAR-T). Methods We retrospectively analyzed the clinical data of patients with refractory/relapsed acute B-lymphoblastic leukemia treated with CD19-CAR-T cells in Beijing Ludaopei hospital from May 2017 to May 2020 . The peripheral blood cell parameters were compared between 46 patients with minimal residual disease (MRD) negative (MRD negative group) and 38 patients with minimal residual disease positive (MRD positive group) after CAR-T cells therapy. Results The mean values of leukocytes, hemoglobin, platelets and neutrophils(LHPN0) in the MRD negative group were significantly higher than those in the MRD positive group on the day of CAR-T cells transfusion, and the differencewas statistically significant (P<0.05). The mean platelet values on the 7th, 14th and 21st day (PLT7, PLT14, PLT21)after CD19-CAR-T cells transfusion were significantly higher in the MRD negative group than those in the MRD positive group, respectively, and the differencewas statistically significant (P<0.05). Conclusion The higher value of LHPN0, PLT7, PLT14, PLT21 may indicate that CD19-CAR-T cell treatment may be effective. The hematopoietic recovery is faster after CD19-CAR-T treatment than after chemotherapy.

Key words: acute lymphoblastic leukemia, chimeric antigen receptor, platelet, relapsed, refractory

CLC Number:

R733.7

ZHANG Zhan-Qiang, ZHANG Gai-Ling, SU Yun-Chao, HE Jiu-Jiang, ZHANG Min, YANG Jun-Fang, ZHANG Xian. The Effect of Peripheral Blood Cell Paremeters in the Patients with Refractory/Relapsed Acute B-Lymphoblastic Leukemia Treated with CD19 -CAR- T Cells[J]. ZHONGHUA YANGSHENG BAOJIAN, 2022, 40(14): 1-4.

References

[1] Hunger SP, Mullighan CG.Acute Lymphoblastic Leukemia in Children[J].N Engl J Med,2015,373:1541-1552.
[2] Benjamin R, Graham C, Yallop D, et al.Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies[J].Lancet,2020,396:1885-1894.
[3] Maus MV.CD19 CAR T cells for adults with relapsed or refractory acute lymphoblastic leukaemia[J].Lancet,2021,398:466-467.
[4] Maude SL, Laetsch TW, Buechner J, et al.Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia[J].N Engl J Med,2018.378:439-448.
[5] Malard F, Mohty M.Acute lymphoblastic leukaemia[J].Lancet,2020,395:1146-1162.
[6] Lee DW, Gardner R, Porter DL, et al.Current concepts in the diagnosis and management of cytokine release syndrome[J].Blood,2014,124:188-195.
[7] Shimabukuro-Vornhagen A, Böll B, Schellongowski P, et al.Critical care management of chimeric antigen receptor T-cell therapy recipients[J].CA Cancer J Clin,2022,72:78-93.
[8] Neelapu SS, Tummala S, Kebriaei P, et al.Chimeric antigen receptor T-cell therapy-assessment and management of toxicities[J].Nat Rev Clin Oncol,2018,15:47-62.
[9] Couzin-Frankel J.Breakthrough of the year 2013. Cancer immunotherapy[J].Science,2013,342:1432-1433.
[10] McNutt M. Cancer immunotherapy[J].Science,2013,342:1417.
[11] Subburaj D, Vaidyanathan L, Uppuluri R, et al.Hematopoietic Stem Cell Transplantation for Childhood Acute Lymphoblastic Leukemia and the Role of MRD: A Single Centre Experience from India[J].Indian J Hematol Blood Transfus,2018,34:43-47.
[12] Wang ZD, Wang YW, Xu LP, et al.Predictive Value of Dynamic Peri-Transplantation MRD Assessed By MFC Either Alone or in Combination with Other Variables for Outcomes of Patients with T-Cell Acute Lymphoblastic Leukemia[J].Curr Med Sci,2021,41:443-453.
[13] Park JH, Rivière I, Gonen M, et al.Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia[J].N Engl J Med,2018,378:449-459.
[14] Zeidler L, Zimmermann M, Möricke A, et al.Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome[J].Haematologica,2012,97:402-409.
[15] Wang Y, Zhang G, Ye L, et al.Clinical value of the quantitation of average daily platelet increase during the recovery period in childhood acute lymphoblastic leukaemia[J].Platelets,2019,30:923-926.
[16] Dai Q, Shi R, Zhang G, et al.Combined use of peripheral blood blast count and platelet count during and after induction therapy to predict prognosis in children with acute lymphoblastic leukemia[J].Medicine (Baltimore),2021,100:e25548.
[17] Faude S, Wei J, Muralidharan K, et al.Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse[J].Blood Adv,2021,5:2128-2136.